Clinical update on cancer: molecular oncology of head and neck cancer.
Head and neck cancers encompass a heterogeneous group of tumours that, in general, are biologically aggressive in nature. These cancers remain difficult to treat and treatment can cause severe, long-term side effects. For patients who are not cured by surgery and/or (chemo)radiotherapy, there are few effective treatment options. Targeted therapies and predictive biomarkers are urgently needed in order to improve the management and minimise the treatment toxicity, and to allow selection of patients who are likely to benefit from both nonselective and targeted therapies. This clinical update aims to provide an insight into the current understanding of the molecular pathogenesis of the disease, and explores the novel therapies under development and in clinical trials.
Department of Molecular Oncology, King's College London, Guy's Hospital, Hodgkin Building, London SE1 1NU, UK.
Y
Y
Suh
Medical Research Council, Toxicology Unit, Leicester University, Leicester LE1 9HN, UK.
I
I
Amelio
Clinical Oncology Department, Lambeth Wing, St Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, UK.
T
T
Guerrero Urbano
Department of Molecular Oncology, King's College London, Guy's Hospital, Hodgkin Building, London SE1 1NU, UK.
M
M
Tavassoli
D000818:Animals; D015415:Biomarkers; D006258:Head and Neck Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D058990:Molecular Targeted Therapy; D015398:Signal Transduction
D015415:Biomarkers